<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/01/2013</AwardEffectiveDate>
<AwardExpirationDate>08/31/2019</AwardExpirationDate>
<AwardTotalIntnAmount>275000.00</AwardTotalIntnAmount>
<AwardAmount>383030</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>03070000</Code>
<Directorate>
<Abbreviation>MPS</Abbreviation>
<LongName>Direct For Mathematical &amp; Physical Scien</LongName>
</Directorate>
<Division>
<Abbreviation>DMR</Abbreviation>
<LongName>Division Of Materials Research</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Randy Duran</SignBlockName>
<PO_EMAI>rduran@nsf.gov</PO_EMAI>
<PO_PHON>7032925326</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The Biomaterials program in the Division of Materials Research funds the collaborative efforts of researchers at Purdue University and Virginia Polytechnic Institute to develop purpose-designed polymeric crystallization inhibitors to enhance drug solubility, and thereby enhancing the delivery of new drugs with improved therapeutic activity. Oral drug therapy is a key aspect of disease treatment, but many exciting new therapeutic agents fail because of poor water solubility. Such drugs do not reach adequate solution concentrations to be therapeutically effective. Using the amorphous form of the drug, which is a high energy form, can lead to much higher solution concentrations and higher levels of drug delivery to the body. The disadvantage of using amorphous formulations is that they are inherently unstable, frequently crystallizing during production, storage or delivery to the body, and thereby negating any solubility advantage. Although crystallization can be delayed or prevented by incorporating polymeric additives, the range of polymers with suitable properties is limited and the properties of off-the-shelf polymers properties are not optimal.  The main aim of this project is to develop synthetic routes in producing novel orally biocompatible polysaccharide amphiphiles designed to inhibit solid and solution phase crystallization of drugs, and at the same time providing desired drug release profiles. Furthermore, the specific structural features governing drug-polymer intermolecular interaction and crystallization inhibition will be elucidated. The technological impact of the project is in creating improved delivery technologies for poorly water-soluble drugs, development of novel drug delivery processes and improved disease treatments. Increasingly, drug developers are interested in solubility enhancement strategies, and these researchers could benefit greatly from the fundamental understanding created by this research. Research findings will be integrated into teaching through undergraduate research activities involving underrepresented minority students, and development of new teaching materials based on this research.&lt;br/&gt;&lt;br/&gt;Providing patients with new and effective drugs, manufactured as tablets or capsules that can be taken orally, is a key aspect of treating chronic and acute diseases. Unfortunately, many of the new drugs currently being tested have poor solubility in water. The goal of this research is to improve the solubility of new drugs by combining them with novel polymers based on polysaccharides, which are natural, renewable, and abundant materials. These polymers will be synthesized and tested for their ability to improve the solubility and stability of drugs. By properly designing the polymer, it will interact with the drug and the solubility of the drug will be improved because the polymer will prevent it from crystallizing, and thus enhancing its solubility. This research will create improved delivery technologies for poorly water-soluble drugs, if the project is successful. Hence, this research could broadly improve disease treatment, and contribute to success of the drug development process. Research findings will be integrated into teaching through undergraduate research activities, and development of new teaching materials based on this project. Through summer undergraduate research programs at Purdue University and Virginia Tech, students will be recruited and mentored in research activities in the investigators' labs with the active participation of graduate students and faculty members.</AbstractNarration>
<MinAmdLetterDate>07/15/2013</MinAmdLetterDate>
<MaxAmdLetterDate>08/10/2018</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.049</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1309218</AwardID>
<Investigator>
<FirstName>Lynne</FirstName>
<LastName>Taylor</LastName>
<PI_MID_INIT>S</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Lynne S Taylor</PI_FULL_NAME>
<EmailAddress>lstaylor@purdue.edu</EmailAddress>
<PI_PHON>7654966614</PI_PHON>
<NSF_ID>000339817</NSF_ID>
<StartDate>07/15/2013</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Purdue University</Name>
<CityName>West Lafayette</CityName>
<ZipCode>479072114</ZipCode>
<PhoneNumber>7654941055</PhoneNumber>
<StreetAddress>Young Hall</StreetAddress>
<StreetAddress2><![CDATA[155 S Grant Street]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<StateCode>IN</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>IN04</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>072051394</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PURDUE UNIVERSITY</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>072051394</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[Purdue University]]></Name>
<CityName>West Lafayette</CityName>
<StateCode>IN</StateCode>
<ZipCode>479072091</ZipCode>
<StreetAddress><![CDATA[575 Stadium Mall Drive]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IN04</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1253</Code>
<Text>OFFICE OF MULTIDISCIPLINARY AC</Text>
</ProgramElement>
<ProgramElement>
<Code>7222</Code>
<Text>XC-Crosscutting Activities Pro</Text>
</ProgramElement>
<ProgramElement>
<Code>7623</Code>
<Text>BIOMATERIALS PROGRAM</Text>
</ProgramElement>
<ProgramReference>
<Code>1515</Code>
<Text>MINORITY GRADUATE EDUC ACTIVIT</Text>
</ProgramReference>
<ProgramReference>
<Code>1711</Code>
<Text>MATERIALS EDUCATION AND RESEARCH</Text>
</ProgramReference>
<ProgramReference>
<Code>7573</Code>
<Text>BIO-RELATED MATERIALS RESEARCH</Text>
</ProgramReference>
<ProgramReference>
<Code>7623</Code>
<Text>BIOMATERIALS PROGRAM</Text>
</ProgramReference>
<ProgramReference>
<Code>9102</Code>
<Text>WOMEN, MINORITY, DISABLED, NEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9282</Code>
<Text>MINORITY GRADUATE RESEARCH</Text>
</ProgramReference>
<Appropriation>
<Code>0113</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0114</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0115</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2013~275000</FUND_OBLG>
<FUND_OBLG>2014~53955</FUND_OBLG>
<FUND_OBLG>2015~54075</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>Enabling formulations are growing in popularity due to the large number of drugs within the pharmaceutical development pipeline that possess poor water solubility. These sophisticated formulation techniques can increase the solubility of the drug in aqueous media and/or aid in their dissolution. Amorphous solid dispersions (ASDs) are of particular interest due to their ability to generate highly supersaturated solutions upon dissolution. Typically, an ASD consists of amorphous drug homogenously blended with an amphiphilic polymer. The polymer has several roles including to facilitate drug release, as well as to inhibit crystallization of the drug from the solid matrix and from the supersaturated solution generated following dissolution. A phenomenon termed liquid-liquid phase separation (LLPS) or glass-liquid phase separation (GLPS) can occur during ASD dissolution when the amorphous solubility is exceeded. Here the drug attains its maximum thermodynamic activity in solution with the excess drug forming a second phase consisting of colloidal amorphous aggregates. It has been hypothesized that the presence of the colloidal amorphous aggregates could be advantageous <em>in vivo</em> since they can act as a drug reservoir and subsequently maintain the drug at its maximum thermodynamic activity in the gastro-intestinal fluid following solution depletion arising from permeation across the gastrointestinal membrane. However, there are few <em>in vivo</em> studies which test this hypothesis. If colloids form, the polymer must also inhibit crystallization from the drug-rich phase. Hence, the polymer has many roles during ASD dissolution making rational polymer design and selection for ASD formulation a complex process. While many studies, both past and present, probe drug release during dissolution, a limited number of studies address a mechanistic understanding of the polymer role during dissolution. We investigated the interplay of the polymer&rsquo;s ability to inhibit crystallization (thought to be primarily through hydrophobic interactions) and to facilitate drug release (via hydrophilic interaction with the aqueous media) on ASD performance, determined the <em>in vivo</em> relevance of colloidal amorphous aggregates. A preliminary correlation was established between <em>in vitro</em> diffusion cell experiments and the amount of drug absorbed in rats. Further, it was found that rapid drug release through use of a relatively hydrophilic polymer is essential, and that the best crystallization inhibitors may be too hydrophobic to achieve adequate release. Therefore, a polymer needs to be an adequate crystallization inhibitor, but be able to release the drug upon oral administration. &nbsp;</p> <p>In terms of crystallization inhibition, the molecular mechanism of stabilization is unclear, making the rational design of new polymers challenging. Here we focused on understanding the effectiveness of polymers to inhibit drug crystallization using experimental and computational modeling approaches. &nbsp;The crystallization inhibition properties of commercial and newly synthesized polymers with various functional groups were studied, and computational modeling was employed to understand variations in polymer intramolecular interactions. Importantly, it was noted that polymers that do not interact well with water are ineffective. A balance between drug-polymer and polymer-water interactions is necessary to achieve and maintain the desired higher solution concentrations. &nbsp;Cellulose derivatives functionalized with carboxylic acids were explored for a group of nine different drugs, and drug-polymer interactions were analyzed through simulations. Polymers that were effective for one drug, were generally effective for other drugs. An optimum degree of substitution with respect to carboxylic acid groups was identified. This will help in the design of even more effective polymers. We achieved insight into the optimization of polymer properties such as chemical functionality and polymer solubility, using the guidance from molecular modeling to understand solution-interactions, with the end goal of contributing to the rational design of new polymers that can be employed to better deliver drugs orally.</p> <p>The results from this study provides the necessary foundation for assessing key polymer properties for effective new drug delivery excipients, ASD phase behavior and performance <em>in vitro</em> in order to make improved <em>in vivo</em> predictions. Ultimately, this research is expected to improve the speed of life-saving drugs progressing through the development pipeline and reduce drug development costs.</p> <p>&nbsp;</p><br> <p>            Last Modified: 11/27/2019<br>      Modified by: Lynne&nbsp;S&nbsp;Taylor</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ Enabling formulations are growing in popularity due to the large number of drugs within the pharmaceutical development pipeline that possess poor water solubility. These sophisticated formulation techniques can increase the solubility of the drug in aqueous media and/or aid in their dissolution. Amorphous solid dispersions (ASDs) are of particular interest due to their ability to generate highly supersaturated solutions upon dissolution. Typically, an ASD consists of amorphous drug homogenously blended with an amphiphilic polymer. The polymer has several roles including to facilitate drug release, as well as to inhibit crystallization of the drug from the solid matrix and from the supersaturated solution generated following dissolution. A phenomenon termed liquid-liquid phase separation (LLPS) or glass-liquid phase separation (GLPS) can occur during ASD dissolution when the amorphous solubility is exceeded. Here the drug attains its maximum thermodynamic activity in solution with the excess drug forming a second phase consisting of colloidal amorphous aggregates. It has been hypothesized that the presence of the colloidal amorphous aggregates could be advantageous in vivo since they can act as a drug reservoir and subsequently maintain the drug at its maximum thermodynamic activity in the gastro-intestinal fluid following solution depletion arising from permeation across the gastrointestinal membrane. However, there are few in vivo studies which test this hypothesis. If colloids form, the polymer must also inhibit crystallization from the drug-rich phase. Hence, the polymer has many roles during ASD dissolution making rational polymer design and selection for ASD formulation a complex process. While many studies, both past and present, probe drug release during dissolution, a limited number of studies address a mechanistic understanding of the polymer role during dissolution. We investigated the interplay of the polymerâ€™s ability to inhibit crystallization (thought to be primarily through hydrophobic interactions) and to facilitate drug release (via hydrophilic interaction with the aqueous media) on ASD performance, determined the in vivo relevance of colloidal amorphous aggregates. A preliminary correlation was established between in vitro diffusion cell experiments and the amount of drug absorbed in rats. Further, it was found that rapid drug release through use of a relatively hydrophilic polymer is essential, and that the best crystallization inhibitors may be too hydrophobic to achieve adequate release. Therefore, a polymer needs to be an adequate crystallization inhibitor, but be able to release the drug upon oral administration.    In terms of crystallization inhibition, the molecular mechanism of stabilization is unclear, making the rational design of new polymers challenging. Here we focused on understanding the effectiveness of polymers to inhibit drug crystallization using experimental and computational modeling approaches.  The crystallization inhibition properties of commercial and newly synthesized polymers with various functional groups were studied, and computational modeling was employed to understand variations in polymer intramolecular interactions. Importantly, it was noted that polymers that do not interact well with water are ineffective. A balance between drug-polymer and polymer-water interactions is necessary to achieve and maintain the desired higher solution concentrations.  Cellulose derivatives functionalized with carboxylic acids were explored for a group of nine different drugs, and drug-polymer interactions were analyzed through simulations. Polymers that were effective for one drug, were generally effective for other drugs. An optimum degree of substitution with respect to carboxylic acid groups was identified. This will help in the design of even more effective polymers. We achieved insight into the optimization of polymer properties such as chemical functionality and polymer solubility, using the guidance from molecular modeling to understand solution-interactions, with the end goal of contributing to the rational design of new polymers that can be employed to better deliver drugs orally.  The results from this study provides the necessary foundation for assessing key polymer properties for effective new drug delivery excipients, ASD phase behavior and performance in vitro in order to make improved in vivo predictions. Ultimately, this research is expected to improve the speed of life-saving drugs progressing through the development pipeline and reduce drug development costs.          Last Modified: 11/27/2019       Submitted by: Lynne S Taylor]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
